Rein Therapeutics, Inc. — fact timeline

Rein Therapeutics, Inc. entered into Underwriting Agreement with Konik Capital Partners, LLC valued at $1.00 per share, before underwriting discounts and commissions (effective 2026-04-30).

“On April 30, 2026, Rein Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an Underwriting Agreement (the “Underwriting Agreement”) with Konik Capital Partners, LLC, a division of T.R. Winston & Company, LLC, acting as sole book-running manager, relating to the issuance and sale of 50,000,000 shares of the Company’s common stock, par value $0.001 per share (the “Offering”).”

Rein Therapeutics, Inc. incurred senior notes of $2,875,000 with three institutional investors at 20% original issue discount maturing the earlier of (i) the date of the closing of the next issuance and sale of securities of the Company, in a single transaction or series of related transactions.

“On February 24 and 27, 2026, Rein Therapeutics, Inc. (the “Company”) entered into separate securities purchase agreements (each a “Purchase Agreement”) with three institutional investors pursuant to which the Company issued and sold to the investors, in a private placement, unsecured promissory notes in the aggregate original principal amount of $2,875,000 (each a “Note”).”

Rein Therapeutics, Inc. entered into Purchase Agreement with three institutional investors valued at $2,875,000.

“On February 24 and 27, 2026, Rein Therapeutics, Inc. (the “Company”) entered into separate securities purchase agreements (each a “Purchase Agreement”) with three institutional investors pursuant to which the Company issued and sold to the investors, in a private placement, unsecured promissory notes in the aggregate original principal amount of $2,875,000 (each a “Note”).”

Rein Therapeutics, Inc. entered into Purchase Agreement with Funicular Funds, LP valued at original principal amount of $2,500,000 (effective 2026-01-15).

“On January 15, 2026, Rein Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with Funicular Funds, LP, a Delaware limited partnership managed by Cable Car Capital, LP (“Funicular”), pursuant to which the Company issued and sold to Funicular, in a private placement, an unsecured promissory note, dated January 15, 2026, in the original principal amount of $2,500,000 (the “Note”).”

Rein Therapeutics, Inc. incurred loan of $2,500,000 with Funicular Funds, LP at 20% original issue discount maturing the earlier of (i) the date of the closing of the next issuance and sale of securities of the Company, in a single transaction or series of related transactions.

“the Company issued and sold to Funicular, in a private placement, an unsecured promissory note, dated January 15, 2026, in the original principal amount of $2,500,000 (the “Note”)”

Rein Therapeutics, Inc. incurred debt of $1.0 million with YA II PN, Ltd. at 8% maturing 12-month anniversary of their issuance.

“(the “Company”, “we”, “us”) in a Current Report on Form 8-K filed on July 30, 2025, on July 29, 2025 (the “Effective Date”), we entered into a Pre-Paid Advance Agreement (the “PPA”) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (“Yorkville”). In accordance with the terms of the PPA, we may request pre-paid advances of up to $6.0 million from Yorkville (each, a “Pre-Paid Advance”) over a 12-month period, subject to certain limitations and conditions set forth in the PPA.”

Rein Therapeutics, Inc. incurred debt of $1.0 million with YA II PN, Ltd. at 8%.

“(the “Company”, “we”, “us”) in a Current Report on Form 8-K filed on July 30, 2025, on July 29, 2025 (the “Effective Date”), we entered into a Pre-Paid Advance Agreement (the “PPA”) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (“Yorkville”). In accordance with the terms of the PPA, we may request pre-paid advances of up to $6.0 million from Yorkville (each, a “Pre-Paid Advance”) over a 12-month period, subject to certain limitations and conditions set forth in the PPA.”

Rein Therapeutics, Inc. incurred credit facility of up to $6.0 million with YA II PN, Ltd. at 8%.

“(the “Company”) entered into a Pre-Paid Advance Agreement (the “PPA”) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (“Yorkville”). In accordance with the terms of the PPA, the Company may request pre-paid advances of up to $6.0 million from Yorkville (each, a “Pre-Paid Advance”) over a 12-month period, subject to certain limitations and conditions set forth in the PPA.”

Rein Therapeutics, Inc.: Amended quorum requirement to 40% of outstanding shares entitled to vote at stockholder meetings (effective 2025-07-10).

“On July 10, 2025, the Board of Directors (the “Board”) of Rein Therapeutics, Inc. (the “Company”) approved an amendment to the Company’s Amended and Restated By-laws (as amended, the “By-laws”), effective immediately, to provide that forty percent (40%) of the shares of capital stock of the Company issued and outstanding and entitled to vote at the meeting, present in person, present by means of remote communication in a manner, if any, authorized by the Board in its sole discretion, or represented by proxy shall constitute a quorum at all meetings of the stockholders for the transaction of business except as otherwise provided by law, the Restated Certificate of Incorporation, as amended, or the By-laws.”

Timothy M. Cunningham was appointed as Interim Chief Financial Officer at Rein Therapeutics, Inc..

“the Board of Directors of Aileron Therapeutics, Inc. (the “Company”) appointed Timothy M. Cunningham, a consultant at Danforth Advisors, LLC (“Danforth”), as interim chief financial officer, effective as of May 16, 2024.”

Charles Garner departed as Chief Financial Officer at Rein Therapeutics, Inc..

“Mr. Garner's departure from the Company on May 15, 2024.”

Rein Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income Net loss for the quarter ended March 31, 2024, was $7.1 million, compared to $4.8 million for the corresponding quarter, EPS The basic and diluted net loss per share for the quarter ended March 31, 2024 was $0.86 compared to $1.05 for the quarte.

“Net loss for the quarter ended March 31, 2024, was $7.1 million, compared to $4.8 million for the corresponding quarter in 2023. The basic and diluted net loss per share for the quarter ended March 31, 2024 was $0.86 compared to $1.05 for the quarter ended March 31, 2023.”

Rein Therapeutics, Inc. entered into Underwriting Agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC valued at combined offering price of $4.68 (effective 2024-05-01).

“On May 1, 2024, Aileron Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Titan Partners Group LLC, a division of American Capital Partners, LLC, as underwriter (the “Underwriter”), relating to an underwritten offering (the “Offering”) of 4,273,505 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and accompanying warrants (“Warrants”) to purchase 4,273,505 shares of Common Stock.”